Q-omics provides the consensus-scored GFI1B profile across patient tissues and cancer cell-line models. GFI1B expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GFI1B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, GFI1B RNA expression shows 10,452 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where GFI1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GFI1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GFI1B survival associations across molecular data types. GFI1B RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GFI1B RNA expression–survival associations across cancer types. High GFI1B expression shows unfavorable associations in ESCA and DLBC, but favorable associations in HNSC, LUAD, UVM and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GFI1B RNA expression.
This table summarizes GFI1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GFI1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GFI1B shows lower tumor expression in COAD, LUAD, READ, THCA and LUSC and higher tumor expression in KIRP. The COAD box plot shows higher GFI1B RNA expression in normal versus tumor tissue (log2 FC = −1.146, t-test p < 0.001).
This table shows molecular features associated with GFI1B in patient tissues and cancer cell lines. In patient samples, GFI1B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GFI1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
